Angray S. Kang

University of London

H指数:29

被引数:5,964

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective

关于理解和管理多发性硬化中低丙种球蛋白血症的临床意见和病例研究：英国视角

MULTIPLE SCLEROSIS AND RELATED DISORDERS

IF2.9

2025-02-010

OAAI

Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study

JOURNAL OF CROHNS & COLITIS

IF8.7

2025-01-220

PRE

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

接种疫苗后血清阴性的多发性硬化症患者的新型冠状病毒肺炎风险

MULTIPLE SCLEROSIS JOURNAL

IF5

2023-07-115

Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IF3.8

2021-11-1815

COVID-19 Vaccine Response in People with Multiple Sclerosis

ANNALS OF NEUROLOGY

IF7.7

2021-11-17120

OAAI

Tallantyre, Emma C.; Vickaryous, Nicola; Anderson, Valerie; Asardag, Aliye Nazli; Baker, David; Bestwick, Jonathan; Bramhall, Kath; Chance, Randy; Evangelou, Nikos; George, Katila; Giovannoni, Gavin; Godkin, Andrew; Grant, Leanne; Harding, Katharine E.; Hibbert, Aimee; Ingram, Gillian; Jones, Meleri; Kang, Angray S.; Loveless, Samantha; Moat, Stuart J.; Robertson, Neil P.; Schmierer, Klaus; Scurr, Martin J.; Shah, Sita Navin; Simmons, Jessica; Upcott, Matthew; Willis, Mark; Jolles, Stephen; Dobson, Ruth

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IF3.8

2020-08-01155

OAAI

Detecting and predicting neutralization of alemtuzumab responses in MS

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION

IF7.5

2020-07-019

OAAI

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies

FRONTIERS IN IMMUNOLOGY